EClinicalMedicine
Study probes neuropsychiatric outcomes of semaglutide use
Semaglutide wasn’t associated with a higher risk of adverse neuropsychiatric outcomes at 12 months compared with sitagliptin, empagliflozin, and glipizide. Potentially beneficial associations were seen for cognitive deficit and nicotine misuse, which warrant further validation in clinical trials.
- For this retrospective cohort study, >100 million patient records were analyzed to compare the risks of 22 neurological and psychiatric outcomes within one year of initiating semaglutide or other antidiabetic medications. Each matched cohort included 23,386 (semaglutide vs. sitagliptin), 22,584 (vs. empagliflozin), and 19,206 (vs. glipizide) patients.
- Semaglutide was associated with reduced risk for the following outcomes: cognitive deficit vs. sitagliptin (hazard ratio[HR], 0.72; 95% CI, 0.64–0.80) and glipizide (HR, 0.72; 95% CI, 0.63–0.81), dementia vs. sitagliptin (HR, 0.52; 95% CI, 0.40–0.68), and nicotine misuse across most comparisons (HR, 0.72; 95% CI, 0.61–0.85 vs. glipizide; HR, 0.77; 95% CI, 0.65–0.90 vs. empagliflozin; HR, 0.82; 95% CI, 0.70–0.95 vs. sitagliptin, though the latter was no longer statistically significant after adjustment for multiple comparisons).
- Empagliflozin showed the fewest differences from semaglutide. No differences in negative control outcomes were observed between cohorts.
Source:
De Giorgi, R. (2024, July 10). EClinicalMedicine. 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00305-5/fulltext